ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...
Formic Joins New American Industrial Alliance, Working Alongside Palantir, Dirac, and More to Restore U.S. Manufacturing Capacity
Press Release Formic, a Robots-as-a-Service (RaaS) automation provider for U.S. manufacturers, announced it has joined the ...